Circulating miR-485-3p as a biomarker for VEGF-associated therapeutic response to atezolizumab plus bevacizumab in hepatocellular carcinoma
Journal of Gastroenterology · 2025
DOI: 10.1007/s00535-025-02239-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gastroenterology, 2025. Verfasst von Kyoko Oura und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki, Kita, Kagawa, 761-0793, Japan. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, MicroRNAs, Vascular Endothelial Growth Factor A. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 23 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: In atezolizumab/bevacizumab (atezo/bev) therapy for unresectable hepatocellular carcinoma (HCC), the tumor immune environment is regulated through vascular endothelial growth factor A (VEGFA) inhibition to maximize immune checkpoint blockade; however, evidence for VEGFA as a biomarker is limited. This study aimed to investigate serum VEGFA and associated microRNAs (miRNAs) as rapid biomarkers and their regulatory mechanisms in the microenvironment of HCC. METHODS: Fifty-four patients with unresectable HCC who were treated with atezo/bev therapy were enrolled and assigned into objective response (OR) and non-OR groups according to the best therapeutic response in 12 weeks using the modified response evaluation criteria in solid tumors. Serum VEGFA levels and associated miRNA expression were compared. Furthermore, the effect of cell transfection with specific miRNA was investigated. RESULT: There was no significant difference in the pre-treatment serum VEGFA levels between the groups; however, the 3-week/pre-treatment ratio of serum VEGFA levels was significantly lower in the OR group than in the non-OR group. The pre-treatment serum levels of 10 miRNAs, especially miR-485-3p involved in VEGFA expression, were higher in the OR group than in the non-OR group and were further elevated after 1-7 days and 3 weeks. MiR-485-3p suppressed HuH-7 migration, enhanced the expression of protein inhibitor of activated (PIA) signal transducer and activator of transcription 3 (STAT3) (PIAS3), and suppressed the expression of phosphorylated STAT3/VEGFA. CONCLUSION: Circulating miR-485-3p is a more sensitive biomarker than VEGFA for the early prediction of therapeutic response in atezo/bev therapy for HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki, Kita, Kagawa, 761-0793, Japan.
- Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki, Kita, Kagawa, 761-0793, Japan. morishita.asahiro@kagawa-u.ac.jp.
- Department of Gastroenterology and Hepatology, Takamatsu Red Cross Hospital, Takamatsu, Kagawa, Japan.
- Department of Gastroenterology, KKR Takamatsu Hospital, Takamatsu, Kagawa, Japan.
- Department of Medical Technology, Kagawa Prefectural University of Health Sciences, Takamatsu, Japan.
- Department of Gastroenterology, Kagawa Saiseikai Hospital, Takamatsu, Japan.
ORCID-Profile: Asahiro Morishita
Zitieren
APA
Oura, K., Morishita, A., Yano, R., Manabe, T., Takuma, K., Nakahara, M., Tadokoro, T., Fujita, K., Mimura, S., Tani, J., Tatsuta, M., Himoto, T., Masaki, T., & Kobara, H. (2025). Circulating miR-485-3p as a biomarker for VEGF-associated therapeutic response to atezolizumab plus bevacizumab in hepatocellular carcinoma. Journal of Gastroenterology. https://doi.org/10.1007/s00535-025-02239-7
Vancouver
Oura K, Morishita A, Yano R, Manabe T, Takuma K, Nakahara M, et al. Circulating miR-485-3p as a biomarker for VEGF-associated therapeutic response to atezolizumab plus bevacizumab in hepatocellular carcinoma. Journal of Gastroenterology. 2025. doi:10.1007/s00535-025-02239-7
BibTeX
@article{Oura2025,
author = {Oura, Kyoko and Morishita, Asahiro and Yano, Rie and Manabe, Takushi and Takuma, Kei and Nakahara, Mai and Tadokoro, Tomoko and Fujita, Koji and Mimura, Shima and Tani, Joji and Tatsuta, Miwa and Himoto, Takashi and Masaki, Tsutomu and Kobara, Hideki},
title = {Circulating miR-485-3p as a biomarker for VEGF-associated therapeutic response to atezolizumab plus bevacizumab in hepatocellular carcinoma},
journal = {Journal of Gastroenterology},
year = {2025},
doi = {10.1007/s00535-025-02239-7}
}
EUVIMED